Prof. Jennifer L. Garst

Duke Raleigh Cancer Center, USA

Email: [email protected]

Qualifications

1990 M.D., Medical College of Georgia

1986 B.Sc., University of Georgia

Publications (selected)

1. Clarke, J. M., Wang, X. F. F., Gu, L., et al. (2020). Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 38(15_suppl), Article e21683.
2. Christensen, J., Garst, J., Wahidi, M., et al. (2017). A Structured Lung Cancer Screening Program Facilitates Patient and Provider Compliance. Journal of Thoracic Oncology, 12(1_suppl), S572.
3. Lynch, T. J., Jr., Spigel, DR., Brahmer, J., et al. (2014). Safety and Effectiveness of Bevacizumab-Containing Treatment for Non-Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohor Study. Journal of Thoracic Oncology, 9(9), 1332–1339.
4. Nayak, L., Omuro, A., DeAngelis, L., et al. (2013). AN OPEN-LABEL, MULTI-CENTER, PHASE II STUDYOF PATUPILONE (EPO906), IN THE TREATMENT OF RECURRENT OR PROGRESSIVE BRAIN METASTASES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC). Neuro-Oncology, 15(suppl_3), 122–123.
5. Nayak, L., Abrey, L., DeAngelis, L., et al. (2013). An Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC). Neurology, 80(suppl), Abstract S56002.
6. Nayak, L., Abrey, L., DeAngelis, L., et al. (2013). An Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC). Neurology, 80(suppl), Abstract IN102005.
7. Porter, L. S., Keefe, F. J., Davis, D., et al. (2012). Attachment styles in patients with lung cancer and their spouses: associations with patient and spouse adjustment. Supportive Care in Cancer, 20(10), 2459–2466.
8. Govindan, R., Bogart, J., Stinchcombe, T., et al. (2011). Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407. Journal of Clinical Oncology, 29(23), 3120–3125.
9. Bastian, L. A., Fish, L. J., Peterson, B. L., et al. (2011). Proactive recruitment of cancer patients' social networks into a smoking cessation trial. Contemporary Clinical Trials, 32(4), 498–504.
10. Porter, L. S., Keefe, F. J., Garst, J., et al. (2011). Caregiver-Assisted Coping Skills Training for Lung Cancer: Results of a Randomized Clinical Trial. Journal of Pain and Symptom Management, 41(1), 1–13.
11. Ready, N., Jänne, P. A., Bogart, J., et al. (2010). Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial. Journal of Thoracic Oncology, 5(9), 1382–1390.
12. Ross, H. J., Blumenschein, G. R., Jr., Aisner, J., et al. (2010). Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research, 16(6), 1938–1949.
13. Daniel, M., Keefe, F. J., Lyna, P., et al. (2009). Persistent Smoking After a Diagnosis of Lung Cancer Is Associated With Higher Reported Pain Levels. Journal of Pain, 10(3), 323–328.
14. Jones, L. W., Eves, N. D., Peterson, B. L., et al. (2008). Safety and Feasibility of Aerobic Training on Cardiopulmonary Function and Quality of Life in Postsurgical Nonsmall Cell Lung Cancer Patients A Pilot Study. Cancer, 113(12), 3430–3439.
15. Porter, L. S., Keefe, F. J., Garst, J., et al. (2008). Self-efficacy for managing pain, symptoms, and function in patients with lung cancer and their informal caregivers: Associations with symptoms and distress. Pain, 137(2), 306–315.
16. Garst, J., Datto, M., Herndon, J. E., II, et al. (2008). A phase II prospective study evaluating the role of pemetrexed plus gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic predictor of cisplatin-resistance to guide therapy. Journal of Clinical Oncology, 26(15_suppl), Abstract 8108.
17. Kelsey, C. R., Boyd, J. A., Hubbs, J. L., et al. (2008). Local/regional recurrence following surgery for early-stage lung cancer: A 10-year experience with 975 patients. Journal of Clinical Oncology, 26(15_suppl), Abstract 7542.

Profile Details
https://medicine.duke.edu/profile/jennifer-lynn-garst
https://www.researchgate.net/profile/Jennifer-Garst
https://www.castleconnolly.com/top-doctors/jennifer-l-garst-medical-oncology-84cc015565

WOS ResearcherID：CSC-7305-2022